TNGX

Tango Therapeutics, Inc.

21.82

USD

-0.71

-3.14%

Oct 30, 14:31 UTC -4

Open

Tango Therapeutics, Inc. (TNGX) Earnings

TNGX Earnings Reports

Positive Surprise Ratio

TNGX beat 12 of 20 last estimates.

60%

Next Report

Date of Next Report

Nov 10, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.35

Implied change from Q2 26 (Revenue/ EPS)

-5.41%

Implied change from Q3 25 (Revenue/ EPS)

-100.00%

-350.00%

Tango Therapeutics, Inc. earnings per share and revenue

On Aug 11, 2026, TNGX reported earnings of -0.37 USD per share (EPS) for Q2 26, missing the estimate of -0.32 USD, resulting in a -13.92% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.81% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an decrease of -5.41% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

PTC Therapeutics, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.34

Actual

$0.61

Surprise

+75.59%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Regeneron Pharmaceuticals Inc

Report Date

Oct 30, 2026 For Q3 26

Estimate

$16.47

Actual

$20.07

Surprise

+21.79%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Insmed, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.46

Surprise

-19.82%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Tango Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Tango Therapeutics, Inc. reported EPS of -$0.37, missing estimates by -13.92%, and revenue of $0.00, 0% as expectations.

How did the market react to Tango Therapeutics, Inc.'s Q2 2026 earnings?

The stock price moved down -4.81%, changed from $27.67 before the earnings release to $26.34 the day after.

When is Tango Therapeutics, Inc. expected to report next?

The next earning report is scheduled for Nov 10, 2026.

What are the forecasts for Tango Therapeutics, Inc.'s next earnings report?

Based on -- analysts, Tango Therapeutics, Inc. is expected to report EPS of -$0.35 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.